Using Hydroxychloroquine (HCQ) to Treat Steatohepatitis

This study is testing whether hydroxychloroquine (HCQ) — a medication already used for conditions like lupus and malaria — can treat fatty liver disease with inflammation (steatohepatitis). The study lasts 12 months. **You may be eligible if...** - You are 18 or older - You have been diagnosed with fatty liver disease (confirmed by ultrasound or MRI) - Your liver has shown signs of ongoing inflammation for more than 3 months (elevated liver enzyme ALT) - You can attend follow-up visits throughout the 12-month study **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have active viral hepatitis (hepatitis B or C) - You are already taking hydroxychloroquine for another condition - You have a known allergy or severe reaction to hydroxychloroquine - You have retinal eye disease (damage to the back of the eye) Talk to your doctor to see if this trial is right for you.